FDA's ODAC Rules Unanimously on a Faster Way to Approve Mult

An FDA advisory committee (ODAC) voted 12-0 today in favor of a major shift in how the agency evaluates new treatments for multiple myeloma. If approved by the

Related Keywords

Miami , Florida , United States , Jenny Ahlstrom , C Ola Landgren , Sean Devlin , Stephend Nimer , Sloan Kettering , National Cancer Institute , Healthtree Foundation , Drug Administration , Oncologic Drugs Advisory Committee , National Heart , International Myeloma Foundation , Myeloma Service , Memorial Sloan Kettering Cancer Center , Sylvester Comprehensive Cancer Center , University Of Miami Miller School Medicine , Sylvester Experimental Therapeutics Program , Sylvester Myeloma Research Institute , Oncologic Drug Advisory Committee , Blood Institute , Miami Miller School , Myeloma Research , Minimal Residual , Multiple Myeloma , Mayo Clinic , Experimental Therapeutics , Newswise , Ultiple Myeloma Minimal Residual Disease Odac Fdac Ola Landgren Sylvester Multiple Institute Oncologic Drugs Advisory Committee ,